Exacis Biotherapeutics Announces Strategic Partnership with CCRM for Specialty Manufacturing of Services and Investment for Development of iPSC-Derived mRNA-Engineered NK Cells

Exacis Biotherapeutics, Inc. announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered natural killer cell products to treat cancer.